Evidence map›Paper›PMID 36906729›Full record

ArticleMolecular biotechnology2023

Development and Characterization of a Novel Single-Chain Antibody Against B-Cell Activating Factor.

Rasoul Mardani-Jouneghani, Shiva Irani, Mahdi Habibi-Anbouhi, Mahdi Behdani

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rasoul Mardani-JouneghaniDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Shiva IraniDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Mahdi Habibi-AnbouhiNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
Mahdi BehdaniBiotechnology Research Centre, Venom and Biotherapeutics Molecules Laboratory, Pasteur Institute of Iran, Tehran, 1316543551, Iran. behdani73042@yahoo.com.ORCID http://orcid.org/0000-0002-4839-5123
Pasteur Institute of Iran · IRIslamic Azad University, Science and Research Branch · IR

Funding

Pasteur Institute of Iran 994
6 · The paper itself

Abstract

As a member of the tumor necrosis factor (TNF) superfamily, the B-cell activating factor (BAFF) plays a crucial role in B-cell survival and differentiation. Overexpression of this protein has been closely linked to autoimmune disorders and some B-cell malignancies. Using monoclonal antibodies (mAbs) against the BAFF soluble domain appears to be a complementary treatment for some of these diseases. This study aimed to produce and develop a specific Nanobody (Nb), a variable camelid antibody domain, against the soluble domain of BAFF protein. After camel immunization with recombinant protein and preparing cDNA from total RNAs separated from camel lymphocytes, an Nb library was developed. Individual colonies capable of binding selectively to rBAFF were obtained by periplasmic-ELISA, sequenced, and expressed in a bacterial expression system. The specificity and affinity of selected Nb were determined and its target identification and functionality were evaluated using flow cytometry.

Indexed as

B-Cell Activating FactorCamelusAnimalsAntibodies, MonoclonalB-LymphocytesInterleukin-4Antibodies, MonoclonalB-Cell Activating FactorInterleukin-4B-cell activating factorCamel immunizationNanobodyTumor necrosis factor

Identifiers

PMID36906729
OpenAlexW4323929111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.